Newspaper article Pittsburgh Post-Gazette (Pittsburgh, PA)

Maker Won't Cut List Price of Drug after 5,000

Newspaper article Pittsburgh Post-Gazette (Pittsburgh, PA)

Maker Won't Cut List Price of Drug after 5,000

Article excerpt

CHICAGO - A small drugmaker that promised to decrease the price of a lifesaving drug - after raising it about 5,000 percent - now says it will not cut the list price of the drug, sold exclusively by select Walgreens pharmacies.

Turing Pharmaceuticals AG, a privately held biopharmaceutical company run by former hedge fund manager Martin Shkreli, caused a furor in September when it acquired the drug, Daraprim, and immediately raised the price of the 62-year-old medicine from $13.50 a tablet to $750 a tablet. The price increase meant some patients or their insurers would suddenly be paying hundreds of thousands of dollars a year.

On Tuesday the drugmaker said it would not cut the list price - the price charged by Walgreens, its exclusive retailer for patients who take the drug after being discharged from a hospital. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed

Oops!

An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.